A REVIEW OF TRULICITY 1.5 MG

The demo realized both of those its Major endpoints, with semaglutide 2.4 mg demonstrating statistically considerable and exceptional enhancements in liver fibrosis without any worsening of steatohepatitis, in addition to resolution of steatohepatitis with no worsening of liver fibrosis in individuals with MASH as compared to placebo.1Semaglutide i